

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/02, A61K 31/44, C07D 513/02 // (C07D 471/02, 221:00, 209:00, 209:00) (C07D 513/02, 333:00, 221:00, 209:00, 209:00)		A1	(11) International Publication Number: WO 96/11929
(21) International Application Number: PCT/EP95/03887	(43) International Publication Date: 25 April 1996 (25.04.96)		
(22) International Filing Date: 2 October 1995 (02.10.95)			(74) Agent: SUMMERSELL, Richard, John; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).
(30) Priority Data: 9420521.8 12 October 1994 (12.10.94) GB			(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(72) Inventors; and			
(75) Inventors/Applicants (for US only): CASSIDY, Frederick [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). HUGHES, Ian [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). RAHMAN, Shahzad, Sharooq [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB). HUNTER, David, James [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).			
(54) Title: BIHETEROARYL-CARBONYL AND CARBOXAMIDE DERIVATIVES WITH 5HT 2C/2B ANTAGONISTS ACTIVITY			
(57) Abstract			
The invention relates to indole and indoline compounds having pharmacological activity, to a process for their preparation, to compositions containing them and to their use in the treatment of CNS disorders (5HT 2C/2B) antagonists.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


**BIHETEROARYL-CARBONYL AND CARBOXAMIDE DERIVATIVES WITH
5HT 2C/2B ANTAGONISTS ACTIVITY**

This invention relates to compounds having pharmacological activity, to a process for their preparation, to compositions containing them and to their use in the treatment of mammals.

WO 95/01976 (SmithKline Beecham plc) describes indoline derivatives which are described as possessing 5HT_{2C} receptor antagonist activity. A structurally distinct class of compounds has now been discovered, which have been found to have 5HT_{2C} receptor antagonist activity. Certain compounds of the invention also exhibit 5HT_{2B} antagonist activity. 5HT_{2C/2B} receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS as well as microvascular diseases such as macular oedema and retinopathy.

Accordingly, in a first aspect, the present invention provides a compound of formula (I) or a salt, solvate or hydrate thereof:

20




wherein:

A, B, C and D are all carbon atoms or one of A, B, C or D is nitrogen and the others are all carbon;

E is oxygen, sulphur, CH₂ or NR¹ where R¹ is hydrogen or C₁₋₆ alkyl;
R² is hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkylthio, nitro, CF₃, cyano, NR⁴R⁵, CONR⁴R⁵, CO₂R⁶ or OR⁷ where R⁴, R⁵, R⁶ and R⁷ are as hydrogen or C₁₋₆ alkyl; and R³ is a group of formula (i)

30




in which:

5 X and Y are both nitrogen, one is nitrogen and the other is carbon or a CH group or one is a CH group and the other is carbon or a CH group;

10 R⁸ and R⁹ groups are independently C₁₋₆ alkyl optionally substituted by one or more halogen atoms, C₂₋₆ alkenyl, C₃₋₆cycloalkyloxy, C₃₋₆cycloalkylC₁₋₆alkoxy, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl-C₁₋₆ alkyl, C₁₋₆ alkylthio, C₃₋₆ cycloalkylthio, C₃₋₆ cycloalkyl-C₁₋₆ alkylthio, C₁₋₆alkoxy, hydroxy, halogen, nitro, CF₃, C₂F₅, OCF₃, SCF₃, SO₂CF₃, SO₂F, formyl, C₂₋₆ alkanoyl, cyano, optionally substituted phenyl or thiienyl, NR⁴R⁵, CONR⁴R⁵ or CO₂R⁶ where R⁴, R⁵ and R⁶ are as defined for R¹; or R⁸ and R⁹ form part of an optionally substituted 5-membered carbocyclic or heterocyclic ring; and

15 R¹⁰ and R¹¹ are independently hydrogen or C₁₋₆ alkyl;

or R³ is a group of formula (ii):




(ii)

20 in which R⁸ and R⁹ are as defined in formula (i), X and Y are both nitrogen, one is nitrogen and the other is a CH group or X and Y are both CH groups; and

R¹² is hydrogen or C₁₋₆ alkyl,

or R³ is a group of formula (iii):

25



in which R⁸, R⁹, X and Y are as defined for formula (i) and Z is oxygen, sulphur, CH₂ or NR¹³ where R¹³ is hydrogen or C₁₋₆ alkyl.

5 C₁₋₆ alkyl moieties whether alone or as part of another group can be straight chain or branched.


Suitably A, B, C and D are all carbon atoms giving an indole ring, or one of A, B, C or D is nitrogen and the others are all carbon giving an azaindole ring, that is to say, a 4-, 5-, 6- or 7-azaindole ring. Preferably A, B and C are all carbon atoms and D is a nitrogen atom, giving a 7-azaindole ring, also known as a pyrrolo[2,3-b]pyridine ring

10 Preferably E is NR¹ where R¹ is hydrogen.

Preferably R² is hydrogen.

Preferably R³ is a group of formula (i). Preferably X and Y form part of a phenyl ring, that is to say one of X or Y is carbon and the other is a CH group or both of X and Y are CH groups. Most preferably R³ is an indoline ring, that is to say a group of

15 formula (A):



in which R⁸ and R⁹ are as defined in formula (i).

20 When R⁸ and R⁹ form part of an aromatic ring suitable rings include thiophene, furan and pyrrole rings. Preferred R⁸ and R⁹ groups, which can be the same or different, include C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, halogen, CF₃, and CO₂R⁶ where R⁶ is hydrogen or C₁₋₆ alkyl. Preferably R⁸ is trifluoromethyl and R⁹ is C₁₋₆alkylthio, for example methylthio.

25 Particularly preferred compounds of formula (I) include:

1-(3-Pyrrolo[2,3-b]pyridylcarbonyl)indoline,

5-Nitro-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,

5-Amino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,

5-Dimethylamino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,

30 5-Diethylamino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,

N-(1-Methyl-5-indolyl)pyrrolo[2,3-b]pyridine-3-carboxamide,

2,3-Dihydro-6-methyl-3-(3-pyrrolo[2,3-b]pyridylcarbonyl)-1H-pyrrolo[3,2-e]indole,

2,3-Dihydro-5-methyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,


N-(1-Methyl-5-indolyl)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide,

2,3-Dihydro-5-methyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,
 2,3-Dihydro-5-ethyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,
 2,3-Dihydro-5-methyl-1-(3-pyrrolo[3,2-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,
 2,3-Dihydro-5-ethyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole
 5 N-(1-Methyl-5-indolyl)pyrrolo[2,3-c]pyridine-3-carboxamide,
 2,3-Dihydro-5-ethyl-1-(3-pyrrolo[2,3-c]pyridylcarbonyl)pyrrolo[2,3-f]indole
 2,3-Dihydro-5-methyl-1-(3-indolylcarbonyl)pyrrolo[2,3-f]indole,
 2,3-Dihydro-5-methyl-1-(1-methyl-3-indolylcarbonyl)pyrrolo[2,3-f]indole
 5-Methoxy-6-trifluoromethyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl) indoline
 10 6-Chloro-5-methyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,
 6,7-Dihydro-5-(3-pyrrolo[2,3-b]pyridylcarbonyl)-5H-thieno[2,3-f] indole,
 or pharmaceutically acceptable salts thereof.

15 The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.


20 The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises the coupling of a compound of formula (II):

25



with a compound of formula (III):

30



wherein A, B, C, and D are as defined in formula (I), E is as defined in formula (I) or is a group $NR^{1'}$, L is a leaving group and X is hydrogen or a metal atom, and the variables, 35 $R^{1'}$, $R^{2'}$ and $R^{3'}$ are R^1 , R^2 and R^3 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any $R^{1'}$, $R^{2'}$ and $R^{3'}$ when other than R^1 , R^2 and R^3 respectively to R^1 , R^2 and R^3 , interconverting R^1 , R^2 and R^3 and forming a pharmaceutically acceptable salt thereof.

Suitably L is a leaving group such as halogen, in particular chloro.


Suitably X is hydrogen or a metal atom such as lithium or magnesium.

Interconversion of a compound of formula (I) into another compound of formula (I) is carried out by conventional procedures well known in the art.

5 For example, in the case wherein R¹ is hydrogen, it is possible to introduce a C₁-C₆alkyl group by conventional alkylation using 1 molar equivalent of a C₁-C₆alkyl halide and 1 molar equivalent of a suitable base in an inert solvent.

10 It should be appreciated that it may be necessary to protect certain reactive groups during coupling reaction (a) above. Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981).

15 Compounds of formula (II) are known compounds or can be prepared from compounds of formula (IV):



in which R², A, B, C, D and E are as defined in formula (II) using standard procedures.

Compounds of formula (III) can be prepared according to the procedures outlined in WO 95/01976. Compounds of formula (IV) are commercially available or 20 can be prepared using standard procedures.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

Compounds of formula (I) and their pharmaceutically acceptable salts have 25 SHT_{2B/2C} receptor antagonist activity and are believed to be of potential use for the treatment or prophylaxis of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of 30 the invention are also expected to be of use in the treatment of certain GI disorders such as IBS as well as microvascular diseases such as macular oedema and retinopathy.

Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.

The invention further provides a method of treatment or prophylaxis of the above disorders, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis the above disorders.

The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable 15 compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

20 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if 25 desired, conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be 30 dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is 35 suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene

oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

5 The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so 10 that the total daily dosage is in the range of about 0.01 to 100 mg; and such therapy may extend for a number of weeks or months.

The following Examples illustrate the preparation of compounds of the invention.

Description 1**N-Acetyl-5-nitroindoline (D1)**

5 A solution of 5-nitroindoline (12 g) in acetic anhydride (150 ml) was treated with pyridine (2 ml). The solution was then heated under reflux for 1 h, cooled and the excess acetic anhydride removed by evaporation *in vacuo*. On addition of water (150 ml), the title compound precipitated as a tan solid (13 g, 86%): ^1H NMR δ (CD₃OD/CDCl₃) 2.29 (3H, s), 3.29 (2H, t, J = 8 Hz), 4.20 (2H, t, J = 8 Hz), 8.04 (1H, s), 8.13 (1H, dd, J = 2, 9 Hz) and 8.3 (1H, d, J = 9 Hz).

10

Description 2**5-Dimethylaminoindoline (D2)**

15 A suspension of N-acetyl-5-nitroindoline (D1) (10 g), 37% aqueous formaldehyde (10 ml), and 5% Pd/C (1.5 g) in ethanol (200 ml) was hydrogenated at a pressure of 45 psi for 18 h. The mixture was then filtered through Kieselguhr, and evaporated to dryness to afford crude N-acetyl-5-dimethylaminoindoline as a white solid. This was dissolved in conc. HCl (6 ml) and heated over a steam bath for 45 minutes. The solution was then basified by dropwise addition of aqueous K₂CO₃ and extracted with 20 chloroform (3 x 20 ml). The organic fraction was dried (MgSO₄) and evaporated *in vacuo* to give an oil. Purification by flash chromatography, eluting with 5% methanol/chloroform gave the title compound as an oil (3.4 g, 86%): ^1H NMR δ (CD₃OD/CDCl₃) 2.8 (6H, s), 3.0 (3H, t, J = 8 Hz), 3.51 (2H, t, J = 8 Hz), 6.61 (2H, m) and 6.75 (1H, br s).

25

Description 3**5-Diethylaminoindoline (D3)**

30 A suspension of N-acetyl-5-nitroindoline (D1) (4 g), excess acetaldehyde (20 ml) and 5% Pd/C (0.5 g) in ethanol (150 ml) was hydrogenated at a pressure of 45 psi for 18 h. The mixture was then filtered through Kieselguhr, and evaporated to dryness to afford crude N-acetyl-5-diethylaminoindoline as a white solid (4.3 g). This was dissolved in conc. HCl (5 ml) and heated over a steam bath for 0.5 h. The solution was then basified by dropwise addition of aqueous K₂CO₃ and extracted with chloroform (3 x 20 ml). The organic fraction was dried (MgSO₄) and evaporated *in vacuo* to give an oil. Purification by flash chromatography, eluting with 5% methanol/chloroform gave the title compound as an oil (3 g, 86%): ^1H NMR δ (CD₃OD/CDCl₃) 1.08 (6H, t, J = 8

Hz), 3.0 (2H, t, *J* = 8 Hz), 3.19 (4H, q, *J* = 7, 14 Hz), 3.52 (2H, t, *J* = 8 Hz), 6.53 (1H, dd, *J* = 2, 8 Hz), 6.6 (1H, d, 8 Hz) and 6.71 (1H, br s).

Description 4

5 1-Methyl-pyrrolo[2,3-b]pyridine-3-carboxylic acid (D4)

A solution of 1-methyl-pyrrolo[2,3-b]pyridine (2.82 g, 21 mmol) and hexamethylenetetramine (4.41 g, 32 mmol) in acetic acid (8.4 ml) and water (17.7 ml) was heated under reflux for 6 h. Water (150 ml) was added and the mixture was extracted 10 with ether. The extracts were washed with water and brine, then dried (Na_2SO_4) and evaporated *in vacuo*. Flash chromatography eluting with ether gave 1-methylpyrrolo[2,3-b]pyridine-3-carboxaldehyde (900 mg, 27%).

A solution of this aldehyde (560 mg, 3.5 mmol) in acetone (20 ml) and sodium 15 carbonate (371 mg, 3.5 mmol) in water (2 ml) was treated over 20 min with a solution of potassium permanganate (1.1 g, 7 mmol) in water (40 ml). Further quantities (2 x 300 mg) of potassium permanganate were added after 30 and 60 min. The mixture was 20 filtered and the solution was evaporated to dryness. The residue was triturated with 50% methanol/ethyl acetate, the resulting solution was evaporated to dryness and the residual solid was triturated with 5% methanol/ethyl acetate to give the title compound as a white 25 solid (390 mg, 63%). Flash chromatography of a sample eluting with 10% ethanol/chloroform gave the title compound: mp 249-251 °C; ^1H NMR δ ($d_6\text{DMSO}$) 3.87 (1H, s), 7.26 (1H, dd, *J* = 5, 8 Hz), 8.24 (1H, s), 8.30 (2H, m) and 12.25 (1H, br s); Found C, 59.81; H, 4.80; N, 15.62; $\text{C}_9\text{H}_8\text{N}_2\text{O}_2 \cdot 0.75 \text{H}_2\text{O}$ requires C, 59.82; H, 4.74; N, 15.51%.

Description 5

2-Nitro-2-pyridylacetic acid, ethyl ester (D5)

30 Ethyl acetoacetate (6.37 ml, 50 mmol) was added dropwise to a stirred suspension of 80% sodium hydride (1.5 g, 50 mmol) in dry DMF (20 ml), keeping the temperature below 50 °C. After 30 min 2-chloro-3-nitropyridine (3.96 g, 25 mmol) was added in portions. The mixture was stirred at room temperature for 90 min and at 70 °C for 1 h, then concentrated *in vacuo*. The residue was diluted with water (150 ml), 35 acidified (HOAc) and extracted with ether. The extracts were washed with water and brine, then dried (Na_2SO_4) and evaporated to leave an orange oil (6.7 ml).

This crude product was dissolved in dry ether (80 ml), made acidic with 1N ethereal HCl and stirred at room temperature overnight. The precipitated solid was filtered off and washed with dry ether to give the HCl salt of the title compound as a pale yellow solid (4.3 g, 70%). The free base was obtained by treating an aqueous solution of 5 the product with 10% sodium carbonate, then extracting with ethyl acetate. After drying (Na_2SO_4) and evaporating the extracts, the title compound was obtained as a yellow oil (3.38 g): ^1H NMR δ (CDCl_3) 1.26 (3H, t, J = 7 Hz), 4.20 (2H, q, J = 7 Hz), 4.34 (2H, s), 7.49 (1H, dd, J = 5, 8 Hz), 8.43 (1H, d, J = 8 Hz) and 8.80 (1H, d, J = 5 Hz).

10 **Description 6**

Ethyl α -(3-nitro-2-pyridyl)- β -dimethylaminoacrylate (D6)

A solution of dimethylformamide diethyl acetal (1.3 ml, 7.5 mmol) in dry DMF (5 ml) was added to a stirred solution of 2-nitro-2-pyridylacetic acid, ethyl ester (D5) (1 15 g, 4.8 mmol) in DMF (20 ml) to give a red solution which was heated at 70 °C overnight. The solution was evaporated *in vacuo* and the residue was extracted repeatedly with boiling hexane. On cooling the title compound separated as red crystals (545 mg, 43%): mp 135-138 °C; ^1H NMR δ (CDCl_3) 1.14 (3H, t, J = 7 Hz), 2.86 (6H, br s), 4.07 (2H, br s), 7.28 (1H, dd, J = 5, 8 Hz), 7.78 (1H, s), 8.19 (1H, d, J = 8 Hz) and 8.76 (1H, d, J = 5 Hz); Found C, 54.40; H, 5.68; N, 15.76; $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}_4$ requires C, 54.33; H, 5.70; N, 20 15.84%.

Description 7

Ethyl pyrrolo[3,2-b]pyridyl-3-carboxylate (D7)

25

A suspension of ethyl α -(3-nitro-2-pyridyl)- β -dimethylaminoacrylate (D6) (0.5 g, 1.9 mmol) in ethanol (150 ml) was hydrogenated over 10% Pd/C at atmospheric pressure for 24 h. The catalyst was filtered off and the solvent was evaporated. The residual solid was chromatographed, eluting with 5% ethanol/ethyl acetate, to give the 30 title compound (250 mg, 70%): mp 213-216 °C (EtOAc); ^1H NMR δ ($d_6\text{DMSO}$) 1.31 (3H, t, J = 7 Hz), 4.27 (2H, d, J = 7 Hz), 7.20 (1H, dd, J = 5, 8 Hz), 7.85 (1H, d, J = 8 Hz), 8.30 (1H, s), 8.48 (1H, d, J = 5 Hz) and 12.1 (1H, br s); Found C, 63.05; H, 5.34; N, 14.73; $\text{C}_{10}\text{H}_{10}\text{N}_2\text{O}_2$ requires C, 63.15; H, 5.30; N, 14.73%.

Description 8**1-Methoxy-4-nitro-2-trifluoromethylbenzene (D8)**

Sodium (11.78g, 0.512 mol) was dissolved in dry methanol (1 l) and to the resulting
5 solution was added a solution of 1-chloro-4-nitro-2-trifluoromethyl-benzene (96.22g,
0.427 mol) in methanol (100 ml). The reaction mixture was refluxed for 3 h then cooled
and evaporated *in vacuo*. The residue was partitioned between water (500 ml) and
dichloromethane (3 x 400 ml). The combined organic extracts were dried (Na_2SO_4) and
evaporated to give the title compound (93.76g, 99%) as a white solid.

10

NMR (CDCl_3) δ : 4.05 (3H, s), 7.12 (1H, d), 8.45 (1H, dd), 8.52 (1H, d).

Description 9**(5-Methoxy-2-nitro-4-trifluoromethylphenyl)acetonitrile (D9)**

15

A mixture of 1-methoxy-4-nitro 2-trifluoromethylbenzene (D8) (93g, 0.421 mol) and 4-chlorophenoxyacetonitrile (77.55g, 0.463 mol) in dry DMF (500 ml) was added dropwise over 0.75 h to a stirred solution of KO^tBu (103.85g, 0.927 mol) in dry DMF (400 ml) at -10° C. After complete addition the resulting purple solution was maintained at -10° C for
20 1 h then poured into a mixture of ice/water (1.5 l) and 5 M aqueous HCl (1.5 l). The resulting mixture was extracted with dichloromethane (3 x 1 l). The combined extracts were washed with water (3 l), dried (Na_2SO_4) and evaporated under reduced pressure. The residue was chromatographed on silica using 10-40% ethyl acetate/petroleum ether as eluant to give the crude product which was recrystallised from ethyl acetate/petroleum
25 ether to afford the title compound (85.13g, 78%) as a white solid. Mp 103-104 °C.

NMR (CDCl_3) δ : 4.10 (3H, s), 4.37 (2H, s), 7.34 (1H, s), 8.53 (1H, s).

Description 10**5-Methoxy-6-trifluoromethylindole (D10)**

(5-Methoxy-2-nitro-4-trifluoromethylphenyl)acetonitrile (D9) (85g, 0.327 mol) in ethanol/water (9:1, 1.6 l) and glacial acetic acid (16 ml) was hydrogenated over 10% palladium on carbon (50 g) at 50 psi for 0.5 h at room temperature. The reaction mixture
35 was filtered and evaporated *in vacuo*. The residue was partitioned between aqueous K_2CO_3 (1 l) and dichloromethane (2 x 1 l) and the combined organic extract was dried (Na_2SO_4) and evaporated to afford the title indole (67.63g, 96%) as a grey solid.

NMR (CDCl₃) δ: 3.94 (3H, s), 6.53 (1H, m), 7.21 (1H, s), 7.32 (1H, m), 7.64 (1H, s), 8.25 (1H, br s).

5 **Description 11**

5-Methoxy-6-trifluoromethylindoline (D11)

The indole (D10) (67.63g, 0.315 mol) was treated with sodium cyanoborohydride (40 g, 0.637 mol) in glacial acetic acid (500 ml) using standard methodology to afford the title 10 indoline (67.73g, 99%) as an off-white solid.

NMR (CDCl₃) δ: 3.07 (2H, t), 3.58 (2H, t), 3.67 (1H, br s), 3.83 (3H, s), 6.83 (1H, s), 6.88 (1H, s).

15 **Example 1**

1-(3-Pyrrolo[2,3-b]pyridylcarbonyl)indoline (E1)

A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (103 mg, 0.635 mmol) in thionyl chloride (5 ml) was heated under reflux for 2 h, then cooled and the excess 20 thionyl chloride evaporated *in vacuo*. The residue in dichloromethane (10 ml) was added in portions to a solution of indoline (76 mg, 0.635 mmol) and triethylamine (193 mg, 1.9 mmol) in dichloromethane (20 ml). The mixture was heated under reflux for 4 h, cooled and diluted with chloroform (20 ml). The solution was washed with water, then dried (MgSO₄) and evaporated *in vacuo*. Flash chromatography, eluting with 10% methanol in chloroform gave the title compound (30 mg, 18%): mp 257-260 °C; ¹H NMR δ 25 (CD₃OD) 3.23 (2H, t, *J* = 10 Hz), 4.42 (2H, t, *J* = 10 Hz), 7.05 (1H, t, *J* = 10 Hz), 7.1-7.35 (3H, m), 7.92 (1H, d, *J* = 8 Hz), 7.99 (1H, s), 8.32 (1H, dd, *J* = 6, 2 Hz) and 8.4 (1H, dd, *J* = 2, 8 Hz); Found C, 72.75; H, 5.10; N, 15.89, C₁₆H₁₃N₃O requires C, 72.99; H, 4.98; N, 15.96%.

30

Example 2

5-Nitro-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline (E2)

A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (1.51 g, 9.3 mmol) in 35 thionyl chloride (20 ml) was heated under reflux for 4 h, then cooled and the excess thionyl chloride evaporated *in vacuo*. The residue in dichloromethane (150 ml) was added in portions to a solution of 5-nitroindoline (1.37 g, 8.4 mmol) and triethylamine

(0.94 g, 27.9 mmol) in dichloromethane (20 ml). The mixture was heated under reflux overnight, cooled and diluted with chloroform (100 ml). The solution was washed with water, then dried (MgSO_4) and evaporated *in vacuo*. Flash chromatography, eluting with 10% methanol in chloroform gave the title compound (0.83 g, 32%): mp 320-322 $^{\circ}\text{C}$; ^1H NMR δ (CD_3OD) 3.3 (2H, overlapping with solvent peak), 4.42 (2H, t, J = 8 Hz), 7.25 (1H, dd, J = 3, 8 Hz), 8.1-8.35 (6H, m), and 8.45 (1H, dd, J = 1.5, 8 Hz); Found C, 59.44; H, 4.01; N, 16.80; $\text{C}_{16}\text{H}_{12}\text{N}_4\text{O}_3\text{H}_2\text{O}$ requires C, 58.89; H, 4.32; N, 17.16%.

Example 3

10 5-Amino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline (E3)

A suspension of 5-nitro-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline (E2) (100 mg) in ethanol (20 ml) was treated with 5% Pd/C (20 mg). The suspension was hydrogenated at 50 psi overnight, then filtered through celite and the solvent evaporated *in vacuo*. The residue was purified by flash chromatography eluting with 5% and then 10% ethanol in chloroform to give the title compound as a solid (34mg, 38%): ^1H NMR δ ($\text{CD}_3\text{OD}/\text{CDCl}_3$) 3.13 (2H, t, J = 8 Hz), 4.32 (2H, t, J = 8 Hz), 6.58 (1H, br d), 6.67 (1H, s), 7.22 (1H, dd, J = 5, 8 Hz), 7.75 (2H, s), 8.3 (1H, dd, J = 1, 5 Hz) and 8.9 (1H, br d); Found C, 65.64; H, 5.09; N, 18.99; $\text{C}_{16}\text{H}_{14}\text{N}_4\text{O}$. 0.75 H_2O requires C, 65.85; H, 5.35; N, 19.19%.

Example 4

25 5-Dimethylamino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline (E4)

A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (306 mg, 1.88 mmol) in thionyl chloride (10 ml) was stirred for 18 h at room temperature. Excess thionyl chloride was evaporated *in vacuo* and the residue dissolved in chloroform was added in portions to a solution of 5-dimethylamino-indoline (305 mg, 1.88 mmol) and triethylamine (570 mg, 5.6 mmol) in chloroform (20 ml). The mixture was heated at 50 $^{\circ}\text{C}$ for 18 h cooled and diluted with chloroform (20 ml). The solution was washed with water, then dried (MgSO_4) and evaporated *in vacuo*. Flash chromatography, eluting with 10% ethanol /dichloromethane gave the title compound (21 mg, 21%): ^1H NMR δ (CD_3OD) 2.93 (6H, s), 3.15 (2H, t, J = 8 Hz), 4.3 (2H, t, J = 8 Hz), 6.58 (1H, br d, J = 9 Hz) 6.69 (1H, s), 7.16 (1H, m), 7.72 (1H, s) 7.88 (1H, br s), 8.36(1H, d, J = 4 Hz) and 8.42(1H, br d, 9 Hz); Found C, 69.73; H, 6.01; N, 17.87; $\text{C}_{18}\text{H}_{18}\text{N}_4\text{O}$. 0.25 H_2O requires C, 69.55; H, 5.99; N, 18.02%.

Example 5**5-Diethylamino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline (E5)**

A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (200 mg, 1.23 mmol) 5 in thionyl chloride (10 ml) was stirred for 18 h at room temperature. Excess thionyl chloride was evaporated *in vacuo* and the residue dissolved in dichloromethane was added in portions to a solution of 5-diethylamino-indoline (235 mg, 123 mmol) and triethylamine (374 mg, 3.74 mmol) in dichloromethane. The mixture was heated at 50 °C for 18 h cooled and the solvent evaporated *in vacuo*. Flash chromatography, eluting 10 with 5% and then 10% ethanol /dichloromethane gave the title compound as a white solid (108 mg, 26%): mp 221-223 °C. ^1H NMR δ (CD₃OD/CD₃Cl) 1.08 (6H, t, J 0 = 7), 3.0 (2H, t, J = 8 Hz), 3.19 (4H, q, J = 7, 14 Hz), 4.35 (2H, t, J = 8 Hz), 6.50 (1H, dd, J = 2, 8 Hz), 6.63 (1H, s), 7.18 (1H, dd, J = 4, 8 Hz), 7.9 (1H, br d), 8.08 (1H, d, J = 2 Hz), 8.3 (1H, m) and 8.39 (1H, d, J = 8 Hz); Found C, 70.87; H, 6.41; N, 16.50; C₂₀H₂₂N₄O. 15 0.25H₂O requires C, 70.88; H, 6.56; N, 16.53%.

Example 6**N-(1-Methyl-5-indolyl)pyrrolo[2,3-b]pyridine-3-carboxamide (E6)**

20 A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid¹ (162 mg, 1 mmol) in thionyl chloride (2 ml) was heated under reflux for 2 h then kept at room temperature overnight. The mixture was evaporated to dryness, then a suspension of the residue in dichloromethane (10 ml) was added in portions to a solution of 1-methyl-5-aminoindole (146 mg, 1 mmol) and triethylamine (0.28 ml, 2 mmol) in dichloromethane (10 ml). 25 After 2 h the mixture was washed with 10% sodium carbonate solution and brine, then was dried (Na₂SO₄) and evaporated *in vacuo*. Flash chromatography, eluting with ethyl acetate gave the title compound (138 mg, 48%): mp 250-253 °C; ^1H NMR δ (d₆DMSO) 3.78 (3H, s), 6.41 (1H, d, J = 4 Hz), 7.23 (1H, dd, J = 8, 4 Hz), 7.32 (1H, d, J = 4 Hz), 7.44 (2H, m), 8.0 (1H, s), 8.32 (1H, d, J = 4 Hz), 8.53 (1H, d, J = 8 Hz) 9.7 (1H, s) and 30 12.2 (1H, s); Found C, 69.95; H, 5.10; N, 18.89; C₁₇H₁₄N₄O requires C, 70.33; H, 4.86; N, 19.30%.

¹Robison, M. M. and Robison, B. L. *J. Am Chem. Soc.*, 1956, 78, 1247

Example 7**2,3-Dihydro-6-methyl-3-(3-pyrrolo[2,3-b]pyridylcarbonyl)-1H-pyrrolo[3,2-e]indole (E7)**

5 A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (162 mg, 1 mmol) in thionyl chloride (4 ml) was heated under reflux for 30 min. The mixture was evaporated *in vacuo* and the residue was added in portions as a suspension in dichloromethane (10 ml) to a solution of 2,3-dihydro-6-methyl-1H-pyrrolo[3,2-e]indole hydrochloride (208 mg, 1 mmol) and triethylamine (0.42 ml, 3 mmol) in dichloromethane (10 ml). After 2 h
10 the dark green solution was washed with water and brine, then dried (Na_2SO_4) and evaporated *in vacuo*. Flash chromatography of the residue, eluting with ethyl acetate gave the title compound (87 mg, 28%): mp 238-245 °C; ^1H NMR δ ($d_6\text{DMSO}$) 3.3 (2H, m), 3.8 (3H, s), 4.48 (2H, t, J = 8 Hz), 6.36 (1H, d, J = 4 Hz), 7.2 (1H, dd, J = 8, 4 Hz), 7.28 (1H, d, J = 9 Hz), 7.36 (1H, d, J = 4 Hz), 8.05 (1H, br d, J = 9 Hz), 8.13 (1H, s),
15 8.32 (1H, d, J = 4 Hz), 8.42 (1H, d, J = 8 Hz) and 12.3 (1H, br s); Found C, 71.16; H, 5.23; N, 17.42; $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}$. 0.25 H_2O requires C, 71.12; H, 5.18; N, 17.46%.

Example 8**2,3-Dihydro-5-methyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole (E8)**

20 A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (D1) (154 mg, 0.95 mmol) in thionyl chloride (3 ml) was heated under reflux for 2 h. The mixture was evaporated *in vacuo* and the residue was added in portions as a suspension in dichloromethane (10 ml) to a solution of 2,3-dihydro-5-methylpyrrolo[2,3-f]indole (120 mg, 0.7 mmol) and triethylamine (0.29 ml, 2.1 mmol) in dichloromethane (20 ml). After 2 h the dark green solution was washed with water and brine, then dried (Na_2SO_4) and evaporated *in vacuo*. Flash chromatography of the residue, eluting with ethyl acetate gave the title compound (40 mg, 14%): mp 266-272 °C; ^1H NMR δ ($d_6\text{DMSO}$) 3.24 (2H, t, J = 8 Hz), 3.76 (3H, s), 4.44 (2H, t, J = 8 Hz), 6.37 (1H, d, J = 3 Hz), 7.22 (2H, m), 7.30 (1H, s), 8.11 (1H, d, J = 2 Hz), 8.31 (1H, d, J = 3 Hz), 8.42 (1H, d, J = 8 Hz) and 12.30 (1H, s); Found C, 72.42; H, 5.31; N, 17.70; $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}$ requires C, 72.14; H, 5.10; N, 17.71%.

Example 9***N*-(1-Methyl-5-indolyl)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide (E9)**

5 A solution of 1-methylpyrrolo[2,3-b]pyridine-3-carboxylic acid (50 mg, 0.28 mmol) in thionyl chloride (1.5 ml) was stirred at room temperature overnight. The mixture was evaporated to dryness, then a suspension of the residue in dichloromethane (5 ml) was added in portions to a solution of 1-methyl-5-aminoindole (45 mg, 0.31 mmol) and triethylamine (0.12 ml, 0.86 mmol) in dichloromethane (10 ml). After 1 h the mixture was evaporated *in vacuo*. Flash chromatography, eluting with ethyl acetate gave 10 the title compound (73 mg, 86%): mp 183-185 °C (EtOAc); ^1H NMR δ (d_6 DMSO) 3.78 (3H, s), 3.92 (3H, s), 6.39 (1H, d, J = 3 Hz), 7.25 (2H, m), 7.42 (2H, m), 8.00 (1H, d, J = 1 Hz), 8.36 (1H, dd, J = 5, 1.5 Hz), 8.44 (1H, s), 8.52 (1H, dd, J = 8, 1.5 Hz) and 9.75 (1H, s); Found C, 69.70; H, 5.36; N, 18.05; $\text{C}_{18}\text{H}_{16}\text{N}_4\text{O}$. 0.25 H_2O requires C, 70.00; H, 5.39; N, 18.14%.

15

Example 10***2,3-Dihydro-5-methyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole (E10)***

20 A mixture of crude 1-methylpyrrolo[2,3-b]pyridine-3-carboxylic acid (176 mg, 1 mmol) in thionyl chloride (3 ml) was stirred at room temperature overnight.. The reagent was evaporated *in vacuo* and the residue was added in portions as a suspension in dichloromethane (10 ml) to a solution of 2,3-dihydro-5-methylpyrrolo[2,3-f]indole (172 mg, 1 mmol) and triethylamine (0.42 ml, 3 mmol) in dichloromethane (10 ml). After 1 h 25 the solution was evaporated *in vacuo*. Flash chromatography of the residue, eluting with ethyl acetate gave the title compound (137 mg, 41%): mp 214-225 °C; ^1H NMR δ (d_6 DMSO) 3.26 (2H, t, J = 7 Hz), 3.76 (3H, s), 3.91 (3H, s), 4.45 (2H, d, J = 7 Hz), 6.38 (1H, d, J = 3 Hz), 7.25 (2H, m), 7.33 (1H, s), 8.27 (1H, s), 8.32 (1H, s), 8.48 (1H, d, J = 3 Hz) and 7.97 (1H, d, J = 6 Hz); M^+ (Found) 330.147186; $\text{C}_{20}\text{H}_{18}\text{N}_4\text{O}$ requires 30 330.148061.

35

Example 11***2,3-Dihydro-5-ethyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole (E11)***

A mixture of crude 1-methylpyrrolo[2,3-b]pyridine-3-carboxylic acid (260 mg, 1.5 mmol) in thionyl chloride (4 ml) was stirred at room temperature overnight. The

reagent was evaporated *in vacuo* and the residue was added in portions as a suspension in dichloromethane (10 ml) to a solution of 2,3-dihydro-5-ethylpyrrolo[2,3-f]indole (280 mg, 1.5 mmol) and triethylamine (0.63 ml, 4.5 mmol) in dichloromethane (25 ml). After 2 h the solution was evaporated *in vacuo*. Flash chromatography of the residue, eluting with ethyl acetate, followed by trituration with ether gave the title compound (165 mg, 32%): mp 210-213 °C; ^1H NMR δ (CDCl₃) 1.48 (3H, t, J = 7 Hz), 3.30 (2H, t, J = 7 Hz), 3.95 (3H, s), 4.15 (2H, q, J = 7 Hz), 4.40 (2H, t, J = 7 Hz), 6.46 (1H, d, J = 3 Hz), 7.08 (1H, d, J = 3 Hz), 7.18 (2H, m), 7.53 (1H, s), 8.20 (1H, br s) and 8.40 (2H, m); Found C, 73.13; H, 5.89; N, 16.11, C₂₁H₂₀N₄O requires C, 73.23; H, 5.85; N, 16.27%.

10

Example 12**2,3-Dihydro-5-methyl-1-(3-pyrrolo[3,2-b]pyridylcarbonyl)pyrrolo[2,3-f]indole (E12)**

15 A solution of ethyl pyrrolo[3,2-b]pyridyl-3-carboxylate (D4) (260 mg, 1.37 mmol) and 2,3-dihydro-5-methylpyrrolo[2,3-f]indole (353 mg, 2.05 mmol) in xylene (20 ml) were heated under reflux for 48 h. The mixture was cooled, filtered, and washed with hexane. The resulting white solid was boiled in methanol (15 ml), cooled and filtered to give the title compound (310 mg, 72%): mp 338-342 °C; ^1H NMR δ (CDCl₃) 3.27 (2H, d, J = 7 Hz), 3.79 (3H, s), 4.4 (2H, m), 6.4 (1H, br s), 7.03 (1H, d, J = 3 Hz), 7.21 (1H, s), 7.25 (1H, m), 7.90 (1H, d, J = 8 Hz), 7.93 (1H, s) and 8.42 (1H, d, J = 3 Hz).

20

Example 13**2,3-Dihydro-5-ethyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole (E13)**

25 A solution of pyrrolo[2,3-b]pyridine-3-carboxylic acid (D1) (200 mg, 1.20 mmol) in thionyl chloride (20 ml) was stirred at room temperature overnight. The mixture was evaporated to dryness and the residue was added in portions to a solution of 2,3-dihydro-5-ethylpyrrolo[2,3-f]indole (230 mg, 1.20 mmol) and triethylamine (0.61 ml, 4.2 mmol) in dichloromethane (20 ml). After 2 h the dark purple solution was 30 washed with water and brine, then dried (Na₂SO₄) and evaporated *in vacuo*. The residue was dissolved in methanol and stirred overnight with activated charcoal, filtered and solvent removed *in vacuo*. Flash chromatography of the residue, eluting with ethyl acetate, gave the title compound (130 mg, 33 %): mp 255-258 °C; ^1H NMR δ (CDCl₃) 1.46 (3H, t, J = 7 Hz), 3.29 (2H, t, J = 8 Hz), 4.12 (2H, q, J = 7 Hz), 4.41 (2H, t, J = 7 Hz), 6.42 (1H, d, J = 2 Hz), 7.05 (1H, d, J = 3 Hz), 7.20 (3H, m), 7.80 (1H, s), 8.40 (1H, d, J = 5 Hz), 8.50 (1H, d, J = 7 Hz) and 11.22 (1H, s); Found C, 72.30; H, 5.62; N, 35 16.67; C₂₀H₁₈N₄O requires C, 72.71; H, 5.49; N, 16.96%.

Example 14***N*-(1-Methyl-5-indolyl)pyrrolo[2,3-c]pyridine-3-carboxamide (E14)**

5 A suspension of pyrrolo[2,3-c]pyridine-3-carboxylic acid¹ (118 mg, 0.73 mmol) in thionyl chloride (5 ml) was heated under reflux overnight at room temperature. The mixture was evaporated to dryness, then a suspension of the residue in dichloromethane (5 ml) was added in portions to a solution of 1-methyl-5-aminoindole (106 mg, 0.73 mmol) and triethylamine (221 mg, 2.2 mmol) in dichloromethane (10 ml). The
10 suspension was heated under reflux for 4 h, then washed with water (2 x 10 ml), dried (MgSO₄) and evaporated *in vacuo* to afford an oil. Flash chromatography, eluting with 5% methanol in chloroform gave the title compound (25 mg, 12%): mp 295-297 °C; ¹H NMR δ (CDCl₃/CD₃OD) 3.8 (3H, s), 6.42 (1H, d, *J* = 4 Hz), 7.15 (1H, d, *J* = 4 Hz), 7.32 (2H, m, *J* = 4 Hz), 7.84 (1H, s), 8.2 (2H, s), 8.33 (1H, br s), 8.7 (1H, br s); Found C, 69.38; H, 4.85; N, 18.72; C₁₇H₁₄N₄O.0.25 H₂O requires C, 69.26; H, 4.87; N, 19.00%.

15

¹Prokopov, A. A. and Yakhontov, L. N. *Khim. Geterotsikl. Soedin.*, 1978, 496

Example 15**2,3-Dihydro-5-ethyl-1-(3-pyrrolo[2,3-c]pyridylcarbonyl)pyrrolo[2,3-f]indole (E15)**

20 A mixture of crude pyrrolo[2,3-c]pyridine-3-carboxylic acid (209 mg, 1.47 mmol) in thionyl chloride (10 ml) was stirred at room temperature overnight. The reagent was evaporated *in vacuo* and the residue was added in portions as a suspension in dichloromethane (5 ml) to a solution of 2,3-dihydro-5-ethylpyrrolo[2,3-f]indole (291 mg, 2.94 mmol) and triethylamine (296 mg, 2.94 mmol) in dichloromethane (5 ml). After 2 h the solution was evaporated *in vacuo*. Flash chromatography of the residue, eluting with 10% ethanol in chloroform, followed by trituration with ether gave the title compound (90 mg, 19%): mp 287-290 °C; ¹H NMR δ (CDCl₃/CD₃OD), 1.48 (3H, t, *J* = 7 Hz), 3.30 (2H, t, *J* = 7 Hz), 4.15 (2H, q, *J* = 15, 7 Hz), 4.38 (2H, t, *J* = 7 Hz), 6.4 (1H, br s), 7.08 (1H, d, *J* = 3 Hz), 7.22 (1H, s), 7.9 (2H, br s), 8.22 (1H, d, *J* = 7 Hz) and 8.75 (1H, s).

Example 16**2,3-Dihydro-5-methyl-1-(3-indolylcarbonyl)pyrrolo[2,3-f]indole (E16)**

A solution of indole-3-carboxylic acid (150 mg, 0.93 mmol) and oxalyl chloride (0.1 ml) in dichloromethane (20 ml) was stirred at room temperature overnight. The mixture was evaporated to dryness and the residue was added in portions to a solution of 2,3-dihydro-5-methylpyrrolo[2,3-f]indole (160 mg, 0.93 mmol) and triethylamine (0.47 ml, 3.2 mmol) in dichloromethane (20 ml). After 2 h the solvent was evaporated *in vacuo* and the residue was purified by flash chromatography, eluting with ethyl acetate, to give the title compound (220 mg, 75 %): mp 279-282 °C; ^1H NMR δ (d_6 DMSO) 3.25 (2H, t, J = 7 Hz), 3.77 (3H, s), 4.41 (2H, t, J = 7 Hz), 6.37 (1H, d, J = 2 Hz), 7.08 - 7.24 (3H, m), 7.33 (1H, s), 7.49 (1H, d, J = 7 Hz), 7.98 (1H, d, J = 2 Hz), 8.05 (1H, d, J = 7 Hz), 8.30 (1H, s); Found C, 74.09; H, 5.60; N, 12.60; $\text{C}_{20}\text{H}_{17}\text{N}_3\text{O}.0.5\text{H}_2\text{O}$ requires C, 74.05; H, 5.59; N, 12.95%.

15

Example 17**2,3-Dihydro-5-methyl-1-(1-methyl-3-indolylcarbonyl)pyrrolo[2,3-f]indole (E17)**

A solution of 1-methylindole-3-carboxylic acid (160 mg, 0.93 mmol) and oxalyl chloride (0.1 ml) in dichloromethane (20 ml) was stirred at room temperature overnight. The mixture was evaporated to dryness and the residue was added in portions to a solution of 2,3-dihydro-5-methylpyrrolo[2,3-f]indole (160 mg, 0.93 mmol) and triethylamine (0.47 ml, 3.2 mmol) in dichloromethane (20 ml). After 2 h the solvent was evaporated *in vacuo* and the residue was purified by flash chromatography, eluting with ethyl acetate, to give the title compound (200 mg, 65 %): mp 242-244 °C; ^1H NMR δ (d_6 DMSO) 3.25 (2H, t, J = 7 Hz), 3.75 (3H, s), 3.88 (3H, s), 4.40 (2H, t, J = 7 Hz), 6.35 (1H, d, J = 2 Hz), 7.12 - 7.32 (4H, m), 7.52 (1H, d, J = 7 Hz), 8.03 (1H, s), 8.07 (1H, d, J = 7 Hz) and 8.30 (1H, s).

30

Example 18**5-Methoxy-6-trifluoromethyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl) indoline (E18)**

To a suspension of pyrrolo [2,3-b] pyridine-3-carboxylic acid (0.16g, 1 mmol) in dry tetrahydrofuran (10 ml) was added oxalyl chloride (85 mL, 1 mmol) and N,N-

35

dimethylformamide (1 drop). After stirring at room temperature for 1 h, a solution of 5-methoxy-6-trifluoromethyl indoline (D11) (0.22g, 1 mmol) and triethylamine (0.19 mL, 2 mmol) in dry tetrahydrofuran (5 mL) was added. The mixture was stirred for 4 h, then

poured into water. The precipitate was filtered off, washed with water and dried. The crude product was recrystallised from dichloromethane/methanol to give the title compound (0.10g, 28%), mp. >250°C.

5 NMR (d_6 DMSO) δ : 3.28 (2H, t, J = 7), 3.89 (3H, s), 4.49 (2H, t, J = 7), 7.21 (1H, dd, J = 7,5), 7.27 (1H, s), 8.17 (1H, s), 8.32 (1H, d, J = 5), 8.41 (1H, s), 8.45 (1H, d, J = 7).

Found M[•] 361

$C_{18}H_{14}N_3O_2F_3$ requires 361

10

Example 19

6-Chloro-5-methyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline (E19)

15 A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (109 mg, 0.67 mmol) in thionyl chloride (5 ml) was stirred for 18 h at room temperature. Excess thionyl chloride was evaporated *in vacuo* and the residue dissolved in dichloromethane was added to a solution of 6-chloro-5-methylindoline (see WO 95/01976) (90 mg, 0.53 mmol) and triethylamine (16 mg, 1.6 mmol) in dichloromethane (5 ml). The mixture was heated at 20 50°C for 18 h cooled and diluted with dichloromethane (20 ml). The solution was washed with water, then dried ($MgSO_4$) and evaporated *in vacuo*. The residue was triturated repeatedly with diethyl ether to give the title compound as a brown solid (22 mg, 14%).

25 1H NMR δ (DMSO): 2.30 (3H, s), 3.15 (2H, t, J = 8Hz), 4.48 (2H, t, J = 8 Hz), 7.20 (1H, m), 7.25 (1H, br s), 8.25 (2H, br s), 8.32 (1H, m), 8.42 (1H, m), HR EI-MS calcd for $C_{18}H_{14}N_3OCl$ (M[•]) 311.0825 found 311.0808.

Example 20

6,7-Dihydro-5-(3-pyrrolo[2,3-b]pyridylcarbonyl)-5H-thieno[2,3-f] indole (E20)

A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (0.5g, 3 mmol) in thionyl chloride (10 ml) was stirred at room temperature for 24 hrs and evaporated to dryness.

35 To a solution of 6,7-dihydro-5H-thieno[2,3-f]indole (see WO 94/22871) (0.49g, 2.8 mmol) in dichloromethane (10 ml) stirring under argon at room temperature was added a solution of the acid chloride in dichloromethane (5 ml). The solution was stirred for 24

hrs and the precipitate collected by suction filtration and recrystallised from ethanol/dichloromethane to afford the title compound (0.18g, 20%) as a green powder, m.pt. 273° - 275°C.

5 ^1H NMR (250 MHz DMSO) δ : 12.35 (br 1H), 8.55 (s, 1H), 8.40 (dd, 1H), 8.26 (m, 1H), 8.12 (m, 1H), 7.80 (s, 1H), 7.51 (d, 1H), 7.36 (d, 1H), 7.17 (m, 1H), 4.46 (t, 2H), 3.23 (t, 2H).

Pharmacological data


**[³H]-mesulergine binding to rat or human 5-HT_{2C} clones expressed in 293 cells in
5 vitro**

Compounds can be tested following the procedure outlined in WO 94/04533.

The compounds of examples 1 to 20 have pKi values of 5.2 to 8.3.

CLAIMS:

1. A compound of formula (I) or a salt, solvate or hydrate thereof:




wherein:

A, B, C and D are all carbon atoms or one of A, B, C or D is nitrogen and the others are all carbon;

10 E is oxygen, sulphur, CH_2 or NR^1 where R^1 is hydrogen or C_{1-6} alkyl;
 R^2 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkylthio, nitro, CF_3 , cyano, NR^4R^5 ,
 CONR^4R^5 , CO_2R^6 or OR^7 where R^4 , R^5 , R^6 and R^7 are as hydrogen or C_{1-6} alkyl; and
 R^3 is a group of formula (i)

15




20

in which:

X and Y are both nitrogen, one is nitrogen and the other is carbon or a CH group or one is a CH group and the other is carbon or a CH group;

25 R^8 and R^9 groups are independently C_{1-6} alkyl optionally substituted by one or more halogen atoms, C_{2-6} alkenyl, C_{3-6} cycloalkyloxy, C_{3-6} cycloalkyl C_{1-6} alkoxy, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-6} alkyl, C_{1-6} alkylthio, C_{3-6} cycloalkylthio, C_{3-6} cycloalkyl- C_{1-6} alkylthio, C_{1-6} alkoxy, hydroxy, halogen, nitro, CF_3 , C_2F_5 , OCF_3 , SCF_3 , SO_2CF_3 , SO_2F , formyl, C_{2-6} alkanoyl, cyano, optionally substituted phenyl or thiienyl, NR^4R^5 , CONR^4R^5 or CO_2R^6 where R^4 , R^5 and R^6 are as defined for R^1 ; or R^8 and R^9 form part of an optionally substituted 5-membered carbocyclic or heterocyclic ring; and


R^{10} and R^{11} are independently hydrogen or C₁₋₆ alkyl;
or R^3 is a group of formula (ii):



5

(ii)

in which R^8 and R^9 are as defined in formula (i), X and Y are both nitrogen, one is nitrogen and the other is a CH group or X and Y are both CH groups; and
10 R^{12} is hydrogen or C₁₋₆ alkyl,
or R^3 is a group of formula (iii):



15

in which R^8 , R^9 , X and Y are as defined for formula (i) and Z is oxygen, sulphur, CH₂ or NR¹³ where R¹³ is hydrogen or C₁₋₆ alkyl.

20

2. A compound according to claim 1 in which R^1 and R^2 are hydrogen

3. A compound according to claim 1 or 2 in which R^3 is a group of formula (i).

25

4. A compound according to any one of claims 1 to 3 in which A, B and C are all carbon and D is nitrogen.

5. A compound according to any one of claims 1 to 4 in which E is NH.


30

6. A compound according to claim 1 which is selected from:
1-(3-Pyrrolo[2,3-b]pyridylcarbonyl)indoline,

5-Nitro-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,
 5-Amino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,
 5-Dimethylamino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,
 5-Diethylamino-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,
 5 N-(1-Methyl-5-indolyl)pyrrolo[2,3-b]pyridine-3-carboxamide,
 2,3-Dihydro-6-methyl-3-(3-pyrrolo[2,3-b]pyridylcarbonyl)-1H-pyrrolo[3,2-e]indole,
 2,3-Dihydro-5-methyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,
 N-(1-Methyl-5-indolyl)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide,
 2,3-Dihydro-5-methyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,
 10 2,3-Dihydro-5-ethyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,
 2,3-Dihydro-5-methyl-1-(3-pyrrolo[3,2-b]pyridylcarbonyl)pyrrolo[2,3-f]indole,
 2,3-Dihydro-5-ethyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole
 N-(1-Methyl-5-indolyl)pyrrolo[2,3-c]pyridine-3-carboxamide,
 2,3-Dihydro-5-ethyl-1-(3-pyrrolo[2,3-c]pyridylcarbonyl)pyrrolo[2,3-f]indole
 15 2,3-Dihydro-5-methyl-1-(3-indolylcarbonyl)pyrrolo[2,3-f]indole,
 2,3-Dihydro-5-methyl-1-(1-methyl-3-indolylcarbonyl)pyrrolo[2,3-f]indole
 5-Methoxy-6-trifluoromethyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl) indoline
 6-Chloro-5-methyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline,
 6,7-Dihydro-5-(3-pyrrolo[2,3-b]pyridylcarbonyl)-5H-thieno[2,3-f] indole
 20 or pharmaceutically acceptable salts thereof.


7. A process for the preparation of a compound according to claim 1 which comprises:
 the coupling of a compound of formula (II):

25



with a compound of formula (III):

30



wherein A, B, C, and D are as defined in formula (I), E is as defined in formula (I) or is a group $NR^{1'}$, L is a leaving group and X is hydrogen or a metal atom, and the variables,

$R^{1'}$, $R^{2'}$ and $R^{3'}$ are R^1 , R^2 and R^3 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any $R^{1'}$, $R^{2'}$ and $R^{3'}$ when other than R^1 , R^2 and R^3 respectively to R^1 , R^2 and R^3 , interconverting R^1 , R^2 and R^3 and forming a pharmaceutically acceptable salt thereof.

- 5 8. A compound according to any one of claims 1 to 6 for use in therapy.
- 10 9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 in association with a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 95/03887

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D471/02 A61K31/44 C07D513/02 // (C07D471/02, 221:00, 209:00, 209:00), (C07D513/02, 333:00, 221:00, 209:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO-A-92 05170 (BEECHAM GROUP PLC) 2 April 1992 see the whole document ---	1-9
Y	J.MED.CHEM., vol. 36, 1993 WASHINGTON, pages 1104-1107, FORBES, I.T. ET AL. 'N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea Hydrochloride : The first selective 5-HT1c Receptor Antagonist' see the whole document ---	1-9
Y	WO,A,94 18196 (WELLCOME FOUND ;NORMAN MARK HENRY (US); NAVAS FRANK III (US)) 18 August 1994 see the whole document ---	1-9 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'B' earlier document but published on or after the international filing date
- 'C' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'D' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'Z' document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
9 February 1996	11.03.96

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentdaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

Inte xial Application No
PCT/EP 95/03887

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO-A-93 18028 (SMITHKLINE BEECHAM PLC) 16 September 1993 see the whole document ---	1-9
Y	WO-A-94 04533 (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); MARTIN ROGER THOM) 3 March 1994 see the whole document ---	1-9
Y	J.MED.CHEM., vol. 29, 1986 WASHINGTON, pages 2415-2418, FLUDZINSKI, P. ET AL. '2,3-Dialkyl(dimethylamino)indoles: Intersctions with 5HT1,5HT2, and Rat Stomach Fundal Serotonin Receptors' see the whole document ---	1-9
P,X	WO-A-95 01976 (SMITHKLINE BEECHAM PLC ;HAM PETER (GB); JONES GRAHAM ELGIN (GB); F) 19 January 1995 see the whole document ---	1-9
P,Y	WO-A-94 22871 (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB); MARTIN ROGER THOM) 13 October 1994 see the whole document ---	1-9
P,Y	WO-A-94 24125 (BOEHRINGER INGELHEIM ITALIA ;GIL QUINTERO MYRNA (IT); MARTINO VINC) 27 October 1994 see the whole document -----	1-9

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 95/03887

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9205170	02-04-92	AU-B-	642941	07-10-93
		AU-B-	8503891	15-04-92
		CA-A-	2091246	14-03-92
		EP-A-	0550507	14-07-93
		JP-T-	6500551	20-01-94
		US-A-	5328922	12-07-94
-----	-----	-----	-----	-----
WO-A-9418196	18-08-94	AU-B-	6005194	29-08-94
		CA-A-	2155758	18-08-94
		EP-A-	0683778	29-11-95
		FI-A-	953777	09-08-95
-----	-----	-----	-----	-----
WO-A-9318028	16-09-93	EP-A-	0630373	28-12-94
		JP-T-	7504429	18-05-95
-----	-----	-----	-----	-----
WO-A-9404533	03-03-94	AU-B-	4704693	15-03-94
		CA-A-	2142721	03-03-94
		CN-A-	1086819	18-05-94
		EP-A-	0656003	07-06-95
		NZ-A-	254785	26-09-95
		SI-A-	9300438	31-03-94
-----	-----	-----	-----	-----
WO-A-9501976	19-01-95	AU-B-	7228394	06-02-95
-----	-----	-----	-----	-----
WO-A-9422871	13-10-94	EP-A-	0691973	17-01-96
-----	-----	-----	-----	-----
WO-A-9424125	27-10-94	AU-B-	6538294	08-11-94
		CA-A-	2160020	27-10-94
		EP-A-	0694033	31-01-96
		FI-A-	954734	05-10-95
		NO-A-	953967	05-12-95
-----	-----	-----	-----	-----